Abbott (ABT) announces Q3 2025 results; uses non-GAAP metrics

Abbott Laboratories reported its third-quarter 2025 results, noting that the information was furnished under Item 2.02 and accompanied by a press release as Exhibit 99.1.

Rhea-AI Filing Summary

Abbott Laboratories reported its third-quarter 2025 results, noting that the information was furnished under Item 2.02 and accompanied by a press release as Exhibit 99.1.

The company highlighted the use of non-GAAP financial measures to evaluate ongoing business performance. These measures adjust for items that can be unusual or unpredictable, including acquisition-related expenses, restructuring actions, fair value changes in contingent consideration, certain regulatory costs, adjustments tied to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit from resolution of prior-year tax positions, and excess tax benefits from share-based compensation. They also exclude intangible amortization expense to show results excluding these costs. Management believes these metrics provide useful insight for investors, while cautioning they should be considered alongside GAAP results.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Abbott (ABT) announce in this 8-K?

Abbott announced its results of operations for the third quarter 2025 and furnished a press release as Exhibit 99.1.

Which non-GAAP adjustments does Abbott (ABT) reference?

Adjustments include acquisition and restructuring expenses, fair value changes to contingent consideration, certain regulatory costs, tax-related items, and excluding intangible amortization expense.

Why does Abbott (ABT) use non-GAAP measures?

Management believes they help investors evaluate ongoing performance and uses them internally to monitor business performance.

How does Abbott (ABT) advise using non-GAAP results?

Abbott cautions that non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP results.

Where can I find the detailed results for ABT’s Q3 2025?

In the press release furnished as Exhibit 99.1.

When were ABT’s Q3 2025 results announced?

October 15, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/15/2025 - 07:33 AM EDT Learn about SEC filing dates

0000001800FALSENew York Stock ExchangeCHX00000018002025-10-152025-10-150000001800exch:XCHI2025-10-152025-10-150000001800exch:XNYS2025-10-152025-10-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

_______________________________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

October 15, 2025

Date of Report (Date of earliest event reported)

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

_______________________________________________________

Illinois

1-2189

36-0698440

(State or other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification  No.)

_______________________________________________________

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (224) 667-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

Title of Each Class			Trading Symbol(s)			Name of Each Exchange on Which Registered
Common Shares, Without Par Value			ABT			New York Stock Exchange NYSE Texas

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02    Results of Operations and Financial Condition

On October 15, 2025, Abbott Laboratories announced its results of operations for the third quarter 2025.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, fair value adjustments to the contingent consideration related to business acquisitions, certain regulatory costs, adjustments related to prior recognition of a significant non-cash deferred tax benefit, tax benefits associated with specified items, net tax benefit as a result of the resolution of various tax positions related to prior years, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott’s management internally assesses performance. Abbott’s management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott’s results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott’s management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

Item 9.01    Financial Statements and Exhibits

Exhibit No.						Exhibit
99.1						Press Release dated October 15, 2025 (furnished pursuant to Item 2.02).
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ABBOTT LABORATORIES
Date: October 15, 2025			By:			/s/ Philip P. Boudreau
						Philip P. Boudreau
						Executive Vice President, Finance and Chief Financial Officer